The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Sarcoid-like granulomatosis (endo-/extrathoracic)
Publications
Soto F, Torre-Sada LF, Mott FE, Kim ST, Nurieva R, Shannon VR, Faiz SA, Casal RF, Altan M, Lin J, Sheshadri A
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.
Journal of immunotherapy and precision oncology 2023 May;6;111-116 — 2023 May — 111-116
Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.
Case reports in oncology 2017 Sep-Dec;10;1070-1075 — 2017 Sep-Dec — 1070-1075
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
La Revue de medecine interne 2018 Feb;39;130-133 — 2018 Feb — 130-133
Pembrolizumab reactivates pulmonary granulomatosis.
Respiratory medicine case reports 2017;22;126-129 — 2017 — 126-129
Pembrolizumab-associated sarcoidosis.
JAAD case reports 2016 Jul;2;290-3 — 2016 Jul — 290-3
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
Annals of oncology : official journal of the European Society for Medical Oncology 2016 06;27;1178-9 — 2016 06 — 1178-9